A Multicenter, Phase 2 Study of Tesetaxel Plus Three Different PD-(L)1 Inhibitors in Patients With Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly and Non-Elderly Adult Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Latest Information Update: 04 Aug 2022
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Tesetaxel (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms CONTESSA TRIO
- Sponsors Odonate Therapeutics
- 26 Jul 2021 Status changed from recruiting to discontinued.(The Sponsor has discontinued the development of tesetaxel).
- 21 May 2021 This trial has been discontinued in Spain (Global End Date: 22 Mar 2021), according to European Clinical Trials Database record.
- 24 Apr 2021 This trial is discontinued in Germany (Trial End Date: 22 Mar 2021), according to European Clinical Trials Database record.